16th May 2011
A new study which has been completed in America has shown the need for doctors to adopt a more personalised approach to cancer treatment in patients suffering from acute myeloid leukaemia (AML).
Researchers at the Wake Forest Baptist Medical Center discovered that the same treatment cannot be given to patients who are suffering from different types of this leukaemia, which is the most common among adults, particularly the elderly,
Using mice they discovered that a particular mutation of a receptor can dictate whether or not a particular treatment is successful.
They tested a combination of drugs on mice with regular AML and others with this particular mutation and discovered that the ones with the mutation died whether or not they received the medication.
Lead author Timothy Pardee said: "We're hopeful that in the future, these findings will lead to more personalised patient care. The 'one-size-fits-all' approach to treating AML needs to be re-examined."
Around 2,000 adults are diagnosed with AML in the UK every year, according to Macmillan.
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.